

October 25, 2022

To,

The Managing Director
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

The Managing Director
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai- 4500051

Subject: Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.


Dear Sirs,

Please find enclosed, disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 in relation to the acquisition of 67,416,540 equity shares issued by Piramal Pharma Limited to Caisse De Dépôt Et Placement Du Québec.

Kindly take the same on record.

Thank you,
Sincerely,

On behalf of **Caisse De Dépôt Et Placement Du Québec**



Authorized Signatory

Gabriel Perras

Senior Legal Counsel

Legal Affairs, Investments

Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Piramal Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Caisse De Dépôt Et Placement Du Québec		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. National Stock Exchange Of India Limited. 2. BSE Limited.		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	N.A.	N.A.	N.A.
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N.A.	N.A.	N.A.
c) Voting rights (VR) otherwise than by equity shares	N.A.	N.A.	N.A.
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	N.A.	N.A.	N.A.
e) Total (a+b+c+d)	67,416,540 equity shares	5.65%	5.65%
Details of acquisition	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
a) Shares carrying voting rights acquired	67,416,540 equity shares	5.65%	5.65%
b) VRs acquired otherwise than by equity shares	N.A.	N.A.	N.A.
c) Warrants/convertible securities/any other instrument that entitles the acquirer to	N.A.	N.A.	N.A.

receive shares carrying voting rights in the TC (specify holding in each category) acquired			
d) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	N.A.	N.A.	N.A.
e) Total (a+b+c+/-d)	67,416,540 equity shares	5.65%	5.65%
After the acquisition, holding of acquirer along with PACs of:	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
a) Shares carrying voting rights	67,416,540 equity shares	5.65%	5.65%
b) VRs otherwise than by equity shares	N.A.	N.A.	N.A.
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	N.A.	N.A.	N.A.
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N.A.	N.A.	N.A.
e) Total (a+b+c+d)	67,416,540 equity shares	5.65%	5.65%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Pursuant to the Composite Scheme of Arrangement amongst Piramal Enterprises Limited, Piramal Pharma Limited, Convergence Chemicals Private Limited, Hemmo Pharmaceuticals Private Limited, PHL Fininvest Private Limited and their respective Shareholders and Creditors ('Scheme') as approved by NCLT.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	N.A.		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	October 19, 2022 (See Note 1)		
Equity share capital / total voting capital of the TC before the said acquisition	No. of shares: 1,18,59,13,506 Amount: INR 10/- each		

	(See Note 2)
Equity share capital/ total voting capital of the TC after the said acquisition	No. of shares: 1,19,33,18,500 Amount: INR 10/- each
Total diluted share/voting capital of the TC after the said acquisition	No. of shares: 1,19,33,18,500 Amount: INR 10/- each

Note 1: Pursuant to the Composite Scheme of Arrangement amongst Piramal Enterprises Limited, Piramal Pharma Limited, Convergence Chemicals Private Limited, Hemmo Pharmaceuticals Private Limited, PHL Fininvest Private Limited and their respective Shareholders and Creditors (“**Scheme**”) as approved by NCLT, Piramal Pharma Limited has allotted shares to the existing shareholders of Piramal Enterprises Limited on 05th September, 2022. However, the trading for shares of Piramal Pharma Limited commenced from 19th October, 2022.

Note 2: Pursuant to the Scheme, all existing shareholders of Piramal Enterprises Limited (including CDPQ) were simultaneously issued shares by Piramal Pharma Limited. Accordingly, based on the filings made by Piramal Pharma Limited with the jurisdictional registrar of companies and the Scheme, prior to the said simultaneous allotments, we note that the paid up share capital of Piramal Pharma Limited was as aforementioned.

Gabriel Perras

Signature of the acquirer / Authorised Signatory

Gabriel Perras

Senior Legal Counsel

Legal Affairs, Investments

Place: Montréal, Québec, Canada, H2Z 2B3

Date: October 25, 2022

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI (Listing Obligations Disclosure Requirements) Regulation, 2015 (erstwhile Clause 35 of the Listing Agreement).

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.